TP新辅助化疗方案治疗Ib-Ⅱa期局部晚期宫颈癌的临床效果观察  被引量:7

Clinical Efficacy of Neoadjuvant Chemotherapy with TP Scheme in Treatment of Local late Stage Ib-Ⅱa Cervical Cancer

在线阅读下载全文

作  者:刘国东 李欣 孟伟旭 任翔[2] 李嘉航[2] 

机构地区:[1]沈阳军区联勤部第一分部第三二一医院肿瘤科,吉林白城137000 [2]解放军第三军医大学学员旅一营,重庆400038

出  处:《现代生物医学进展》2014年第12期2267-2270,共4页Progress in Modern Biomedicine

基  金:国家自然科学基金项目(30872464)

摘  要:目的:观察并探讨宫颈癌术前行TP与PF两种新辅助化疗方案的临床效果,优选新辅助化疗方案。方法:将2008年1月-2010年12月间入选的91例Ib-Ⅱa宫颈癌患者随机分为A(n=46)、B(n=45)两组,A组患者子宫切除术前予TP新辅助化疗方案,B组予PF方案,各2个周期,对比化疗结束后两组临床疗效、化疗期间药物毒性反应及术后2年内宫颈癌复发率。结果:①A、B两组总体有效率分别为89.1%、82.2%,差异不具有统计学意义(P>0.05),但前者化疗后瘤体直径明显小于B组(P<0.05);②两组药物毒性反应构成不具有统计学差异(P>0.05),但A组胃肠道反应与肝脏毒性发生率明显低于B组(P<0.05);③A、B两组组术后2年内宫颈癌复发率分别为2.2%、11.9%,复发率无统计学差异(P>0.05)。结论:宫颈癌术前TP新辅助化疗方案较之BIP方案具有比较优势,更具备临床推广价值。Objective:The paper is to investigate and explore the clinical effect of cervical cancer underwent TP or PF two kinds of neoadjuvant chemotherapy(NACT),and to prefer the better neoadjuvant chemotherapy scheme.Methods:91 cases from Jan.2008 to Dec.2010 were randomized divided into A(n=46) B(n=45) group,group A was given TP(DDP +TAX) NACT scheme before radical hysterectomy,group B was given PF(DDP+5-Fu) scheme,and each with 2 treatment cycles,comparison on clinical effect after NACT,drug toxicity and recurrence rate within 2 years after hysterectomy were conducted between 2 groups.Results:①0verall efficiency of A,B group were 89.1%,82.2% respectively,the difference was not statistically significant(P〉0.05),but the diameter of tumor of group A after chemotherapy was significantly less than that of group B(P〈0.05);②Constitution of drug toxicity of 2 groups was not statistically different(P〉0.05),but the incidence rate of gastrointestinal reaction liver toxicity of group A was significantly lower than that of group B(P〈0.05);③Recurrence rates of A B group within 2 years after surgery were 2.2%,11.9% respectively,also with no significant difference(P〉0.05).Conclusion:Neoadjuvant chemotherapy of TP scheme compared with BIP scheme has comparative advantage,and have more clinical value of popularization.

关 键 词:宫颈癌 新辅助化疗 顺铂 紫杉醇 疗效 

分 类 号:R737.31[医药卫生—肿瘤]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象